Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.58% to $644.19 Wednesday, on what proved to be an all-around great ...

Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...

Michael Burry boosted his positions in apparel, healthcare, and scientific stocks, while trimming major holdings, showing a ...

According to Benzinga Pro, Regeneron Pharmaceuticals Inc's peer group average for short interest as a percentage of float is ...

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more about ALNY stock here.

Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...

Regeneron Pharmaceuticals recently completed a study titled Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry. The study ...

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Stock futures were little changed Tuesday, a day after major indexes set fresh intraday and closing records for a second straight session, as a highly anticipated Federal Reserve meeting was set to ...